Drug Profile
IPX 159
Alternative Names: IPX-159Latest Information Update: 15 May 2018
Price :
$50
*
At a glance
- Originator Impax Pharmaceuticals
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Restless legs syndrome
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 28 Feb 2013 Discontinued - Phase-II for Restless legs syndrome in Australia (PO)
- 28 Feb 2013 Discontinued - Phase-II for Restless legs syndrome in USA (PO)